Related Experiment Video
Updated: Feb 28, 2026

Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator
Published on: May 19, 2023
The TMAO-Producing Enzyme Flavin-Containing Monooxygenase 3 Regulates Obesity and the Beiging of White Adipose Tissue
Rebecca C Schugar1, Diana M Shih2, Manya Warrier1
1Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA; Center for Microbiome and Human Health, Cleveland Clinic, Cleveland, OH 44195, USA.
Abstract:
Emerging evidence suggests that microbes resident in the human intestine represent a key environmental factor contributing to obesity-associated disorders. Here, we demonstrate that the gut microbiota-initiated trimethylamine N-oxide (TMAO)-generating pathway is linked to obesity and energy metabolism. In multiple clinical cohorts, systemic levels of TMAO were observed to strongly associate with type 2 diabetes. In addition, circulating TMAO levels were associated with obesity traits in the different inbred strains represented in the Hybrid Mouse Diversity Panel. Further, antisense oligonucleotide-mediated knockdown or genetic deletion of the TMAO-producing enzyme flavin-containing monooxygenase 3 (FMO3) conferred protection against obesity in mice. Complimentary mouse and human studies indicate a negative regulatory role for FMO3 in the beiging of white adipose tissue. Collectively, our studies reveal a link between the TMAO-producing enzyme FMO3 and obesity and the beiging of white adipose tissue.
Insights
The gut microbe-generated compound trimethylamine N-oxide (TMAO) is linked to obesity and type 2 diabetes. Reducing the TMAO-producing enzyme flavin-containing monooxygenase 3 (FMO3) protected mice against obesity.
Area of Science:
- Microbiology
- Metabolic disorders
- Obesity research
Background:
- Gut microbiota plays a crucial role in host energy metabolism and is implicated in obesity-associated disorders.
- Trimethylamine N-oxide (TMAO) is a metabolite produced by gut microbes, and its role in metabolic diseases is under investigation.
Purpose of the Study:
- To investigate the link between the gut microbiota-initiated TMAO-generating pathway and obesity and energy metabolism.
- To explore the association of TMAO levels with type 2 diabetes and obesity traits.
- To determine the role of flavin-containing monooxygenase 3 (FMO3) in obesity and adipose tissue beiging.
Main Methods:
- Analysis of systemic TMAO levels in human clinical cohorts and the Hybrid Mouse Diversity Panel.
- Investigating the effect of FMO3 knockdown or genetic deletion on obesity in mice.
- Examining the regulatory role of FMO3 in white adipose tissue beiging using mouse and human studies.
Main Results:
- Systemic TMAO levels strongly associated with type 2 diabetes in human cohorts.
- Circulating TMAO levels correlated with obesity traits across different inbred mouse strains.
- FMO3 inhibition or deletion conferred protection against obesity in mice.
- FMO3 was found to negatively regulate the beiging of white adipose tissue.
Conclusions:
- The TMAO-generating pathway initiated by gut microbiota is linked to obesity and impaired energy metabolism.
- FMO3 is a key enzyme in TMAO production and plays a significant role in regulating body weight and adipose tissue function.
- Targeting FMO3 may represent a potential therapeutic strategy for obesity and related metabolic disorders.
Related Concept Videos
Obesity
Regulation of Metabolism
Regulation of Food Intake

